Clinical trial
MAD Refractory: Solid Tumor QD w/o Break
NCT00207012 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00207012 |
|---|---|
| Title | MAD Refractory: Solid Tumor QD w/o Break |
| Official title | Continuous Dosing Phase I Study of BMS-599626 in Patients With HER2-Expressing Advanced Solid Malignancies |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HER2 or EGFR Expressing Advanced Solid Malignancies |
| Intervention type | Drug |
| Interventions | BMS-599626 |
| Enrollment | 45 |
| Start date | May 1, 2004 |
| Primary completion | Feb 1, 2006 |
| First posted | Sep 21, 2005 |
| Last update posted | Mar 2, 2010 |
| Countries | France, Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: